Organic compounds -- part of the class 532-570 series – Organic compounds – Amino nitrogen containing
Reexamination Certificate
2006-10-31
2006-10-31
Kumar, Shailendra (Department: 1621)
Organic compounds -- part of the class 532-570 series
Organic compounds
Amino nitrogen containing
C564S162000, C564S170000, C514S616000, C514S617000, C514S618000, C514S619000, C514S620000
Reexamination Certificate
active
07129377
ABSTRACT:
The present invention relates to an androgen receptor alkylating compound, wherein the compound may include, inter alia, an active functional group, which permits the alkylation of the androgen receptor.
REFERENCES:
patent: 3875229 (1975-04-01), Gold
patent: 4139638 (1979-02-01), Neri et al.
patent: 4191775 (1980-03-01), Glen
patent: 4239776 (1980-12-01), Glen et al.
patent: 4282218 (1981-08-01), Glen et al.
patent: 4386080 (1983-05-01), Crossley et al.
patent: 4465507 (1984-08-01), Konno et al.
patent: 4636505 (1987-01-01), Tucker
patent: 4880839 (1989-11-01), Tucker
patent: 5162504 (1992-11-01), Horoszewicz
patent: 5609849 (1997-03-01), Kung
patent: 5656651 (1997-08-01), Sovak et al.
patent: 6019957 (2000-02-01), Miller et al.
patent: 6071957 (2000-06-01), Miller et al.
patent: 6160011 (2000-12-01), Miller et al.
patent: 6482861 (2002-11-01), Miller et al.
patent: 6492554 (2002-12-01), Dalton et al.
patent: 6569896 (2003-05-01), Dalton et al.
patent: 6838484 (2005-01-01), Steiner et al.
patent: 2003/0225040 (2003-12-01), Dalton et al.
patent: 2003/0232792 (2003-12-01), Dalton et al.
patent: 2004/0014975 (2004-01-01), Dalton et al.
patent: 2004/0087557 (2004-05-01), Steiner et al.
patent: 0 040 932 (1981-12-01), None
patent: 0 100 172 (1984-02-01), None
patent: 000 2892 (1985-02-01), None
patent: 0 253 503 (1988-01-01), None
patent: 1360001 (1970-03-01), None
patent: 52-128329 (1977-10-01), None
patent: 54-63047 (1980-12-01), None
patent: WO 95/19770 (1995-07-01), None
patent: WO 98 05962 (1998-02-01), None
patent: WO 98/53826 (1998-12-01), None
patent: WO 98/55153 (1998-12-01), None
patent: WO 01 27622 (2001-04-01), None
patent: WO 01 28990 (2001-04-01), None
patent: WO 01 34563 (2001-05-01), None
patent: WO 02 00617 (2002-01-01), None
patent: WO 02/016310 (2002-02-01), None
Tucker et al, J. Med. Chem., 1988, 31, 885-887.
Chang et al, “Affinity labeling of the androgen receptor in rat prostate cyto with 17 beta-[(bromoacetyl)oxy]-5alpha-androstan-3-one” Biochemistry (1984) 22:23(11):2527-33.
Tucker et al “Resolution of the nonsteroidal antiandrogen 4′Ocyano‘3’[(4-fluorophenyl) sulfonyl]-2-hydroxy-2-methyl-3′-(trifluoromet) propionanilide and the determination of the absolute cnfiguraiton of the active enantiomer” J. Med. Chem (1988) 31(4):885-7.
Tucker et al “Nonsteroidal antiandrogens. Syntheses and structure-activity relationships of 3-substituted derivatives of 2-hydroxypropionanilides” J. Med. Chem (1988) 31(5):954-9.
McCammon et al “An androgenic affinity Ligand covalently binds to cytosolic aldehyde dehydrogenase from human genital skin fibroblasts” Mol Cell Endocrinol (1993) 91(1-2):177-83.
Soloway MS et al “Antiandrogenic agents as monotherapy in advanced prostatic carcinoma” Cancer (1993) 1:71(3 suppl):1083-8.
McConnell JD “Physiologic basis of endocrine therapy for prostatic cancer” Urol. Clin. North Am. (1991), 18;1-13.
Labrie F “Endocrine therapy for prostate cancer” Endocrinol Metab. Clin. North Am.
Denis L et al “Prostatic cancer. An overview” Acta Oncol. (1990)29:665-77.
Catalona William J. “Management of cancer of the Prostate” vol. 331:996-1004 (1994).
Eliason et al., “High Throughput Fluorescence Polarization-Based Screening Assays for the Identification of Novel Nuclear Receptor Ligands,” Abstracts of Papers, 223rd ACS National Meeting, Orlando, FL, United States, (2002), Apr. 7, 2002.
Howard Tucker and Glynne J. Chesterson, J. Med Chem. 1988, 31, pp. 885-887, “Resolution of the Nonsteroidal Antiandrogen—4′-Cyano-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methyl-3′-(trifluoromethyl)-propionanilide and the Determination of the Absolute Configuration of the Active Enantiomer”.
D. McKillop, et al., “Enantioselective metabolism and pharmacokinetics of Casodex in the male rat”, Xenobiotica, 1995, vol. 25, No. 6, 623-634.
Leonid Kirkovsky, et al., “[123I]-Radionated Bicalutamide Analogs as Potential Imaging Agents for Prostate Cancer”, Poster Presentation MEDI 155, 214th ACS National Meeting, Las Vegas, NV, Sep. 7-11, 1997, Department of Pharmaceutical Sciences, University of Tennessee, Memphis, TN 38163.
David T. Baird and Anna F. Glasier, “Hormonal Contraception—Drug Therapy”, The New England Journal of Medicine, May 27, 1993, pp. 1543-1549.
F.C. W. Wu, “Male Contraception: Current Status and Future Prospects”, Clinical Endocrinology, (1988), 29, pp. 443-465.
Carl Djerassi and S.P. Leibo, “A new look at male contraception”, Nature, vol. 370, pp. 11-12.
World Health Organisation Task Force on Methods for the Regulation of Male Fertility, “Contraceptive efficacy of testosterone-induced azoospermia in normal men”, The Lancet, vol. 336, Oct. 20, 1990, pp. 955-959and 1517-1518.
C. G. Francisco, et al., “Long-acting contraceptive agents: testosterone esters of unsaturated acids”, Steroids, Jan. 1990, vol. 55, Butterworths.
John M. Hoberman and Charles E. Yesalis, “The History of Synthetic Testosterone”, Scientific American, Feb. 1995, pp. 76-81.
Leonid Kirkovsky, et al., “Approaches to Irreversible non-steroidal cliiral antiandrogens”, Department of Pharmaceutical Sciences, University of Tennessee, 47th Southeast/51st Southwest Joint Regional Meeting of the American Chemical Society, Memphis, TN, Nov. 29-Dec. 1, 1995.
David J. Handelsman, “Bridging the gender gap in contraception: another hurdle cleared” The Medical Journal of Australia, vol. 154, Feb. 18, 1996, pp. 230-233.
Edwards JP, Higuchi RI, Wiim DT, Pooley CLF, Caferro TR, Hamann LG, Zhi L, Marschke KB, Goldman ME, and Jones TK. Nonsteroidal androgen receptor agonists based on 4-(trifluorometliyl)-2H-pyrano[3,2-g]quinolin-2-one. Bioorg. Med. Chem. Lett., 9: 1003, 1999.
Zhi L, Tegley CM, Marschke KB, and Jones TK. Switching androgen receptor antagonists to agonists by modifying C-ring substituents on piperidino[3,2-g]quinolone. Bioorg. Med. Chem. Lett., 9: 1009, 1999.
Higuchi RI, Edwards JP, Caferro TR, Ringgenberg JD, Kong JW, Hamann LG, Arienti KL, Marschke KB, Davis RL, Farmer LJ, and Jones TK. 4-Alkyl- and 3,4-diaklyl-1,2,3,4-tetrahydro-8-pyridono[5,6-g]quinolines: potent, nonsteroidal androgen receptor agonists. Bioorg. Med. Chem. Lett., 9:1335, 1999.
Hamann LG, Mani NS, Davis RL, Wang XN, Marschke KB, and Jones TK. Discoveiy of a potent, orally active nonsteroidal androgen receptor agonist: 4-ethyl-1,2,3,4-tetrahydro-6-(trifluoromethyl)-8-pyridono[5,6-g]-quinoline (LG121071). J. Med. Chem., 42: 210, 1999.
Rosen J, Day A, Jones TK, Jones ET, Nadzan AM, and Stein RB. Intracellular receptors and signal transducers and activators of transcription superfamilies: novel targets for small-molecule drug discovery. J. Med. Chem., 38: 4855, 1995.
Dalton JT, Mukherjee A, Zhu Z, Kirkovsky L, and Miller DD. Discovery of Nonsteroidal Androgens. Biochem. Biophys. Res. Commun.,244(1):1-4, 1998.
Edwards JP, West SJ, Pooley CLF, Marschke KB, Fanner LJ, and Jones TK. New nonsteroidal androgen receptor modulators based on 4-(tiifluoromethyl)-2-(IH)-Pyrololidino[3,2-gjquinolone. Bioorg. Med. Chem. Lett., 8: 745, 1998.
Berger et al., “Concepts and limitations in the application of radio labeled antiandrogens, estrogens, or androgens as isotropic scanning agents for the prostate”, Invest. Urol, (1975), 1391, 10-16.
Dalton James T.
Kirkovsky Leonid I.
Miller Duane D.
Mukherjee Arnab
Cohen Mark S.
Kumar Shailendra
Pearl Cohen Zedek Latzer LLP
University of Tennessee Research Foundation
LandOfFree
Irreversible non-steroidal antagonist compound and its use... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Irreversible non-steroidal antagonist compound and its use..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Irreversible non-steroidal antagonist compound and its use... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3682957